# Orthopediatrics Corp: financial statements, quarterly

KIDS · Nasdaq · CIK 1425450 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kids.md) · [Financials](/companies/kids/financials.md) · [Filings](/companies/kids/filings.md) · [Insiders](/companies/kids/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kids/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [40.0](/filings/0001425450-24-000094.md) | [37.6 d](/filings/0001425450-26-000013.md) | [44.7](/filings/0001425450-25-000052.md) | [52.8](/filings/0001425450-25-000096.md) | [54.6](/filings/0001425450-25-000114.md) | [52.7 d](/filings/0001425450-26-000013.md) | [52.4](/filings/0001425450-26-000036.md) | [61.1](/filings/0001425450-26-000070.md) | [61.3](/filings/0001425450-25-000114.md) | [61.6 d](/filings/0001425450-26-000013.md) | [59.4](/filings/0001425450-26-000036.md) | [70.5](/filings/0001425450-26-000070.md) |
| Cost of revenue | $m | [9.0](/filings/0001425450-24-000094.md) | [10.9 d](/filings/0001425450-26-000013.md) | [12.5](/filings/0001425450-25-000052.md) | [12.0](/filings/0001425450-25-000096.md) | [14.5](/filings/0001425450-25-000114.md) | [17.1 d](/filings/0001425450-26-000013.md) | [14.1](/filings/0001425450-26-000036.md) | [17.1](/filings/0001425450-26-000070.md) | [16.0](/filings/0001425450-25-000114.md) | [16.5 d](/filings/0001425450-26-000013.md) | [16.0](/filings/0001425450-26-000036.md) | [18.1](/filings/0001425450-26-000070.md) |
| Gross profit | $m | [31.0](/filings/0001425450-24-000094.md) | [26.7 d](/filings/0001425450-26-000013.md) | [32.2](/filings/0001425450-25-000052.md) | [40.8](/filings/0001425450-25-000096.md) | [40.1](/filings/0001425450-25-000114.md) | [35.6 d](/filings/0001425450-26-000013.md) | [38.3](/filings/0001425450-26-000036.md) | [44.0](/filings/0001425450-26-000070.md) | [45.3](/filings/0001425450-25-000114.md) | [45.1 d](/filings/0001425450-26-000013.md) | [43.4](/filings/0001425450-26-000036.md) | [52.4](/filings/0001425450-26-000070.md) |
| Research and development | $m | [2.6](/filings/0001425450-24-000094.md) | [2.9 d](/filings/0001425450-26-000013.md) | [3.0](/filings/0001425450-25-000052.md) | [2.5](/filings/0001425450-25-000096.md) | [2.6](/filings/0001425450-25-000114.md) | [2.9 d](/filings/0001425450-26-000013.md) | [2.4](/filings/0001425450-26-000036.md) | [2.2](/filings/0001425450-26-000070.md) | [2.3](/filings/0001425450-25-000114.md) | [2.3 d](/filings/0001425450-26-000013.md) | [2.2](/filings/0001425450-26-000036.md) | [2.3](/filings/0001425450-26-000070.md) |
| Operating income | $m | [(4.5)](/filings/0001425450-24-000094.md) | [(8.1) d](/filings/0001425450-26-000013.md) | [(9.7)](/filings/0001425450-25-000052.md) | [(5.7)](/filings/0001425450-25-000096.md) | [(5.6)](/filings/0001425450-25-000114.md) | [(14.1) d](/filings/0001425450-26-000013.md) | [(11.0)](/filings/0001425450-26-000036.md) | [(10.7)](/filings/0001425450-26-000070.md) | [(9.4)](/filings/0001425450-25-000114.md) | [(8.2) d](/filings/0001425450-26-000013.md) | [(8.3)](/filings/0001425450-26-000036.md) | [(4.1)](/filings/0001425450-26-000070.md) |
| Interest expense | $m | [0.0](/filings/0001425450-24-000094.md) | [(0.3) d](/filings/0001425450-26-000013.md) | [0.6](/filings/0001425450-25-000052.md) | [0.3](/filings/0001425450-25-000096.md) | [0.4](/filings/0001425450-25-000114.md) | [1.3 d](/filings/0001425450-26-000013.md) | [1.1](/filings/0001425450-26-000036.md) | [1.1](/filings/0001425450-26-000070.md) | [1.8](/filings/0001425450-25-000114.md) | [1.9 d](/filings/0001425450-26-000013.md) | [2.1](/filings/0001425450-26-000036.md) | [2.5](/filings/0001425450-26-000070.md) |
| Income tax | $m | [0.8](/filings/0001425450-24-000094.md) | [(0.2) d](/filings/0001425450-26-000013.md) | [(2.5)](/filings/0001425450-25-000052.md) | [(0.0)](/filings/0001425450-25-000096.md) | [(1.2)](/filings/0001425450-25-000114.md) | [(0.3) d](/filings/0001425450-26-000013.md) | [0.2](/filings/0001425450-26-000036.md) | [0.0](/filings/0001425450-26-000070.md) | [(0.1)](/filings/0001425450-25-000114.md) | [0.3 d](/filings/0001425450-26-000013.md) | [(0.2)](/filings/0001425450-26-000036.md) | [0.2](/filings/0001425450-26-000070.md) |
| Net income | $m | [(4.6)](/filings/0001425450-24-000094.md) | [(6.7) d](/filings/0001425450-26-000013.md) | [(7.8)](/filings/0001425450-25-000114.md) | [(6.0)](/filings/0001425450-25-000114.md) | [(7.9)](/filings/0001425450-25-000114.md) | [(16.1) d](/filings/0001425450-26-000013.md) | [(10.7)](/filings/0001425450-26-000070.md) | [(7.1)](/filings/0001425450-26-000070.md) | [(11.8)](/filings/0001425450-25-000114.md) | [(10.1) d](/filings/0001425450-26-000013.md) | [(10.7)](/filings/0001425450-26-000070.md) | [(7.2)](/filings/0001425450-26-000070.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001425450-24-000094.md) | not reported | [(0.34)](/filings/0001425450-25-000052.md) | [(0.26)](/filings/0001425450-25-000096.md) | [(0.34)](/filings/0001425450-25-000114.md) | not reported | [(0.46)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) | [(0.50)](/filings/0001425450-25-000114.md) | not reported | [(0.45)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001425450-24-000094.md) | not reported | [(0.34)](/filings/0001425450-25-000052.md) | [(0.26)](/filings/0001425450-25-000096.md) | [(0.34)](/filings/0001425450-25-000114.md) | not reported | [(0.46)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) | [(0.50)](/filings/0001425450-25-000114.md) | not reported | [(0.45)](/filings/0001425450-26-000036.md) | [(0.30)](/filings/0001425450-26-000070.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.6](/filings/0001425450-23-000114.md) | [31.1](/filings/0001425450-25-000015.md) | [21.6](/filings/0001425450-24-000033.md) | [28.9](/filings/0001425450-24-000079.md) | [51.0](/filings/0001425450-24-000094.md) | [43.8](/filings/0001425450-26-000013.md) | [33.4](/filings/0001425450-25-000052.md) | [44.6](/filings/0001425450-25-000096.md) | [16.8](/filings/0001425450-25-000114.md) | [19.6](/filings/0001425450-26-000070.md) | [12.2](/filings/0001425450-26-000036.md) | [17.0](/filings/0001425450-26-000070.md) |
| Current assets | $m | [226](/filings/0001425450-23-000114.md) | [226](/filings/0001425450-25-000015.md) | [204](/filings/0001425450-24-000033.md) | [194](/filings/0001425450-24-000079.md) | [248](/filings/0001425450-24-000094.md) | [237](/filings/0001425450-26-000013.md) | [232](/filings/0001425450-25-000052.md) | [258](/filings/0001425450-25-000096.md) | [246](/filings/0001425450-25-000114.md) | [256](/filings/0001425450-26-000070.md) | [246](/filings/0001425450-26-000036.md) | [253](/filings/0001425450-26-000070.md) |
| Total assets | $m | [432](/filings/0001425450-23-000114.md) | [439](/filings/0001425450-25-000015.md) | [437](/filings/0001425450-24-000033.md) | [431](/filings/0001425450-24-000079.md) | [489](/filings/0001425450-24-000094.md) | [473](/filings/0001425450-26-000013.md) | [470](/filings/0001425450-25-000052.md) | [504](/filings/0001425450-25-000096.md) | [493](/filings/0001425450-25-000114.md) | [509](/filings/0001425450-26-000070.md) | [502](/filings/0001425450-26-000036.md) | [511](/filings/0001425450-26-000070.md) |
| Current liabilities | $m | [47.9](/filings/0001425450-23-000114.md) | [41.7](/filings/0001425450-25-000015.md) | [45.8](/filings/0001425450-24-000033.md) | [39.6](/filings/0001425450-24-000079.md) | [34.6](/filings/0001425450-24-000094.md) | [34.0](/filings/0001425450-26-000013.md) | [37.5](/filings/0001425450-25-000052.md) | [38.7](/filings/0001425450-25-000096.md) | [33.2](/filings/0001425450-25-000114.md) | [46.2](/filings/0001425450-26-000070.md) | [47.2](/filings/0001425450-26-000036.md) | [52.9](/filings/0001425450-26-000070.md) |
| Total liabilities | $m | [58.1](/filings/0001425450-23-000114.md) | [61.7](/filings/0001425450-25-000015.md) | [66.6](/filings/0001425450-24-000033.md) | [59.5](/filings/0001425450-24-000079.md) | [118](/filings/0001425450-24-000094.md) | [119](/filings/0001425450-26-000013.md) | [123](/filings/0001425450-25-000052.md) | [148](/filings/0001425450-25-000096.md) | [144](/filings/0001425450-25-000114.md) | [162](/filings/0001425450-26-000070.md) | [163](/filings/0001425450-26-000036.md) | [168](/filings/0001425450-26-000070.md) |
| Long-term debt | $m | not reported | [9.9](/filings/0001425450-25-000015.md) | [10.2](/filings/0001425450-24-000033.md) | [9.8](/filings/0001425450-24-000079.md) | [72.5](/filings/0001425450-24-000094.md) | [73.0](/filings/0001425450-26-000013.md) | [73.0](/filings/0001425450-25-000052.md) | [97.0](/filings/0001425450-25-000096.md) | [99.2](/filings/0001425450-25-000114.md) | [99.8](/filings/0001425450-26-000070.md) | [100](/filings/0001425450-26-000036.md) | [99.5](/filings/0001425450-26-000070.md) |
| Current portion of debt | $m | not reported | [0.2](/filings/0001425450-25-000015.md) | [0.2](/filings/0001425450-24-000033.md) | [0.2](/filings/0001425450-24-000079.md) | [0.6](/filings/0001425450-24-000094.md) | [0.9](/filings/0001425450-26-000013.md) | [0.9](/filings/0001425450-25-000052.md) | [0.8](/filings/0001425450-25-000096.md) | [1.5](/filings/0001425450-25-000114.md) | [1.9](/filings/0001425450-26-000070.md) | [2.2](/filings/0001425450-26-000036.md) | [2.5](/filings/0001425450-26-000070.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [374](/filings/0001425450-24-000094.md) | [377](/filings/0001425450-26-000013.md) | [371](/filings/0001425450-25-000114.md) | [371](/filings/0001425450-25-000114.md) | [371](/filings/0001425450-25-000114.md) | [355](/filings/0001425450-26-000070.md) | [347](/filings/0001425450-26-000070.md) | [356](/filings/0001425450-26-000070.md) | [349](/filings/0001425450-25-000114.md) | [347](/filings/0001425450-26-000070.md) | [339](/filings/0001425450-26-000070.md) | [344](/filings/0001425450-26-000070.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.7) d](/filings/0001425450-24-000094.md) | [(7.5) d](/filings/0001425450-26-000013.md) | [(6.7)](/filings/0001425450-25-000052.md) | [(6.1) d](/filings/0001425450-25-000096.md) | [(10.3) d](/filings/0001425450-25-000114.md) | [(4.0) d](/filings/0001425450-26-000013.md) | [(4.2)](/filings/0001425450-26-000036.md) | [(10.5) d](/filings/0001425450-26-000070.md) | [(0.6) d](/filings/0001425450-25-000114.md) | [10.3 d](/filings/0001425450-26-000013.md) | [(3.3)](/filings/0001425450-26-000036.md) | [0.9 d](/filings/0001425450-26-000070.md) |
| Capital expenditure | $m | [2.5 d](/filings/0001425450-24-000094.md) | [3.8 d](/filings/0001425450-26-000013.md) | [6.5](/filings/0001425450-25-000052.md) | [6.7 d](/filings/0001425450-25-000096.md) | [1.4 d](/filings/0001425450-25-000114.md) | [(0.3) d](/filings/0001425450-26-000013.md) | [4.2](/filings/0001425450-26-000036.md) | [3.4 d](/filings/0001425450-26-000070.md) | [2.8 d](/filings/0001425450-25-000114.md) | [0.6 d](/filings/0001425450-26-000013.md) | [1.8](/filings/0001425450-26-000036.md) | [4.0 d](/filings/0001425450-26-000070.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.3](/filings/0001425450-23-000114.md) | [22.5](/filings/0001425450-24-000033.md) | [22.7](/filings/0001425450-24-000079.md) | [22.8](/filings/0001425450-24-000094.md) | [22.8](/filings/0001425450-25-000052.md) | [23.1](/filings/0001425450-25-000096.md) | [23.2](/filings/0001425450-25-000114.md) | [23.2](/filings/0001425450-26-000036.md) | [23.5](/filings/0001425450-26-000070.md) | [23.6](/filings/0001425450-25-000114.md) | [23.7](/filings/0001425450-26-000036.md) | [24.0](/filings/0001425450-26-000070.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,109,788 at 2026-08-04, from the cover of the [10-Q filed 2026-08-05](/filings/0001425450-26-000070.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.